Advertisement
Canada markets close in 4 hours 15 minutes
  • S&P/TSX

    21,930.93
    +45.55 (+0.21%)
     
  • S&P 500

    5,104.44
    +56.02 (+1.11%)
     
  • DOW

    38,233.12
    +147.32 (+0.39%)
     
  • CAD/USD

    0.7309
    -0.0014 (-0.19%)
     
  • CRUDE OIL

    84.08
    +0.51 (+0.61%)
     
  • Bitcoin CAD

    86,899.13
    -509.95 (-0.58%)
     
  • CMC Crypto 200

    1,320.30
    -76.23 (-5.46%)
     
  • GOLD FUTURES

    2,344.10
    +1.60 (+0.07%)
     
  • RUSSELL 2000

    1,995.05
    +13.93 (+0.70%)
     
  • 10-Yr Bond

    4.6650
    -0.0410 (-0.87%)
     
  • NASDAQ

    15,939.28
    +327.52 (+2.10%)
     
  • VOLATILITY

    15.49
    +0.12 (+0.78%)
     
  • FTSE

    8,145.21
    +66.35 (+0.82%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • CAD/EUR

    0.6836
    +0.0015 (+0.22%)
     

Company News for May 6, 2020

  • Shares of Lumentum Holdings Inc. LITE rose 4.7% after the company reported third-quarter 2020 earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.06.

  • Share of Illinois Tool Works Inc. ITW rose 0.9% after the company reported first quarter earnings of $1.77 per share, surpassing the Zacks Consensus Estimate of $1.71.

  • Shares of Incyte Corporation INCY plunged 2.2% after the company reported first quarter adjusted loss of $2.86 per share in contrast to the Zacks Consensus Estimate of earnings of 8 cents.

  • Shares of Portola Pharmaceuticals, Inc. PTLA jumped more than 100% afterthe company announced it will be acquired by Alexion Pharmaceuticalsfor $18 per share in cash.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Incyte Corporation (INCY) : Free Stock Analysis Report
 
Illinois Tool Works Inc. (ITW) : Free Stock Analysis Report
 
Portola Pharmaceuticals, Inc. (PTLA) : Free Stock Analysis Report
 
Lumentum Holdings Inc. (LITE) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research